• 3 - 5 This report by the Spanish Lymphoma Group (GELTAMO) aims to provide useful guidelines and recommendations for the prevention, diagnosis, and treatment of central nervous system diffuse large B-cell lymphoma patients with, or at risk of, leptomeningeal and/or brain parenchyma lymphoma relapse. (haematologica.org)
  • Several factors hinder the identification of risk factors for central nervous system (CNS) involvement in diffuse large B-cell lymphoma (DLBCL), including the retrospective nature of most studies, the relatively low frequency of CNS relapse in DLBCL, and the heterogeneity of CNS prophylaxis methods used in these studies. (haematologica.org)
  • A form of non-Hodgkin lymphoma having a usually diffuse pattern with both small and medium lymphocytes and small cleaved cells. (lookformedical.com)
  • A group of heterogeneous lymphoid tumors generally expressing one or more B-cell antigens or representing malignant transformations of B-lymphocytes. (lookformedical.com)
  • Any of a group of malignant tumors of lymphoid tissue that differ from HODGKIN DISEASE, being more heterogeneous with respect to malignant cell lineage, clinical course, prognosis, and therapy. (lookformedical.com)
  • Rituximab plus chemotherapy, most often CHOP (cyclophosphamide, doxorubicin, vincristine, and prednisone), is the first-line standard of care for patients with advanced indolent lymphoma, and for elderly patients with mantle-cell lymphoma. (nih.gov)
  • Patients aged 18 years or older with a WHO performance status of 2 or less were eligible if they had newly diagnosed stage III or IV indolent or mantle-cell lymphoma. (nih.gov)
  • 1. Addition of bortezomib to standard dose chop chemotherapy improves response and survival in relapsed mantle cell lymphoma. (nih.gov)
  • 2. Bortezomib-based therapy for newly diagnosed mantle-cell lymphoma. (nih.gov)
  • 3. A phase 1 dose escalation study of bortezomib combined with rituximab, cyclophosphamide, doxorubicin, modified vincristine, and prednisone for untreated follicular lymphoma and other low-grade B-cell lymphomas. (nih.gov)
  • 4. Immunochemotherapy with rituximab and cyclophosphamide, doxorubicin, vincristine, and prednisone significantly improves response and time to treatment failure, but not long-term outcome in patients with previously untreated mantle cell lymphoma: results of a prospective randomized trial of the German Low Grade Lymphoma Study Group (GLSG). (nih.gov)
  • 6. Combined cyclophosphamide, vincristine, doxorubicin, and prednisone (CHOP) improves response rates but not survival and has lower hematologic toxicity compared with combined mitoxantrone, chlorambucil, and prednisone (MCP) in follicular and mantle cell lymphomas: results of a prospective randomized trial of the German Low-Grade Lymphoma Study Group. (nih.gov)
  • 7. Treatment of older patients with mantle-cell lymphoma. (nih.gov)
  • 9. Efficacy and toxicity of 2 schedules of frontline rituximab plus cyclophosphamide, doxorubicin, vincristine, and prednisone plus bortezomib in patients with B-cell lymphoma: a randomized phase 2 trial from the French Adult Lymphoma Study Group (GELA). (nih.gov)
  • 12. Bortezomib plus CHOP-rituximab for previously untreated diffuse large B-cell lymphoma and mantle cell lymphoma. (nih.gov)
  • 2012 Wiley Periodicals, Inc. consecutive consensus conferences, the issues were analyzed and dis- Follicular cell lymphoma (FL) is a frequent disorder for cussed according to the nominal group technique, as previously described [5]. (health-articles.net)
  • In the 2008 WHO classification, grade 3b FL were separated and are universally treated as diffuse large reported the clinical outcomes in patients in which the ther- B-cell lymphoma (DLBCL) [2]. (health-articles.net)
  • Bortezomib ( Velcade , Janssen-Cilag) has been given a positive opinion from the Committee for Medicinal Products for Human Use of the European Medicines Agency for its use in mantle cell lymphoma (MCL). (medscape.com)
  • Cite this: EU Thumbs Up for Bortezomib for Mantle Cell Lymphoma - Medscape - Dec 19, 2014. (medscape.com)
  • The positive opinion is based on data from the phase 3 study, LYM-3002, conducted in 487 patients with newly diagnosed MCL who were ineligible, or not considered, for bone marrow transplantation , which was presented at the 2014 American Society of Clinical Oncology annual meeting ( J Clin Oncol . (medscape.com)
  • High dose chemotherapy followed by hematopoietic stem cell transplant wasrecommended for young fit patients who achieve a response after salvage chemoimmunotherapy. (health-articles.net)
  • We compared bendamustine plus rituximab with CHOP plus rituximab (R-CHOP) as first-line treatment for patients with indolent and mantle-cell lymphomas. (nih.gov)